Corporate News

Alnylam Pharmaceuticals has announced the appointment of Siva Sakhamuri, Ph.D., as its new Chief Technical Officer (CTO). Mr. Sakhamuri is expected to bring a depth of expertise in the technical and manufacturing aspects of biologics, vaccines, oligonucleotides, and RNA‑based therapies, positioning the company to accelerate its RNA therapeutic pipeline and expand its manufacturing footprint.

Professional Background

Mr. Sakhamuri’s career spans several high‑profile biopharmaceutical organizations, where he has consistently overseen critical CMC (Chemistry, Manufacturing, and Control) functions and quality operations. Key highlights include:

  • Alnylam (prior tenure) – Directed CMC readiness for commercial launches of RNA interference (RNAi) products, managing both internal and external manufacturing activities.
  • Orna Therapeutics – Served as CTO, supervising CMC and quality for circular RNA lipid‑nanoparticle (LNP) programs that were later acquired by Eli Lilly in 2026.
  • Omega Therapeutics, Alexion Pharmaceuticals, Sanofi Pasteur, Bristol Myers Squibb – Held senior positions contributing to multiple product launches and regulatory submissions across biologics and vaccine platforms.

This breadth of experience provides Mr. Sakhamuri with a comprehensive understanding of the technical, regulatory, and operational challenges that define the biopharmaceutical landscape.

Strategic Fit for Alnylam

Alnylam’s leadership emphasized that the appointment aligns closely with the company’s strategic priorities:

  • Pipeline Expansion – Alnylam is actively broadening its RNA therapeutic portfolio. Mr. Sakhamuri’s expertise in RNAi and circular RNA technologies is expected to facilitate the efficient translation of early‑stage candidates into commercial products.
  • Manufacturing Scale‑Up – The company’s long‑term success depends on the ability to scale up manufacturing while maintaining product quality and regulatory compliance. Mr. Sakhamuri’s track record of managing both internal and external manufacturing partners positions Alnylam to meet these demands.
  • Competitive Positioning – In a crowded RNA therapeutic market, robust technical operations can serve as a differentiator, enabling quicker product launches and stronger intellectual property protection.

While the announcement did not disclose financial details, the strategic rationale suggests that Alnylam aims to solidify its competitive edge through operational excellence and technical innovation.

Industry Context

The broader biopharmaceutical industry is witnessing accelerated investment in RNA technologies, driven by advances in delivery systems, gene editing, and precision medicine. Companies that can seamlessly integrate scientific discovery with scalable manufacturing are increasingly valued by investors and regulators alike. In this context, Alnylam’s decision to strengthen its technical leadership reflects a broader industry trend toward consolidating operational capabilities with therapeutic innovation.

Conclusion

The appointment of Siva Sakhamuri as CTO marks a pivotal step for Alnylam Pharmaceuticals, reinforcing its commitment to advancing RNA therapeutics through rigorous technical oversight and scalable manufacturing. By leveraging Mr. Sakhamuri’s extensive experience across multiple biopharmaceutical sectors, Alnylam positions itself to navigate the complex regulatory and commercial landscape that defines the RNA therapeutic space.